When combined with other mutations such as TP53, CDKN2A, and KRAS, NRF2 activation promotes cancer initiation, early stages of tumor progression, and resistance to chemotherapy, radiation therapy, and immune checkpoint inhibitors[15]. This evidence concerns the gene NFE2L2 and cancer.